Advanced search
Publication Cover
Aging Health Volume 2, 2006 - Issue 3
Journal homepage
45
Views
0
CrossRef citations to date
0
Altmetric
Review

Ovarian Cancer in Older Women

C Pisano1 Division of Medical Oncology B, National Cancer Institute of Naples, Naples, Italy
,
S Greggi2 Division of Gynecologic Oncology, National Cancer Institute of Naples, Naples, Italy
,
M Falanga1 Division of Medical Oncology B, National Cancer Institute of Naples, Naples, Italy
,
G Laurelli2 Division of Gynecologic Oncology, National Cancer Institute of Naples, Naples, Italy
,
VR Iaffaioli1 Division of Medical Oncology B, National Cancer Institute of Naples, Naples, Italy
&
S Pignata1 Division of Medical Oncology B, National Cancer Institute of Naples, Naples, Italy;3 Divisione di Oncologia Medica B, Istituto Nazionale Tumori, via M. Semmola80131, Naples, Italy Tel.: +39 81 5903637; Fax: +39 81 5903822; E-mail: [email protected]
Pages 437-447 | Published online: 24 May 2006

Bibliography

  • Olshansky SJ , CarnesBA, CasselCK: The ageing of the human species.Sci. Am.268, 46–52(1993).
  • Yancik R : Population aging and cancer: a cross-national concern.Cancer J.11, 437–441(2005).
  • La Vecchia C , LucchiniF, NegriEet al.: Trends of cancer mortality in Europe 1955–89: breast and genital sites.Eur. J. Cancer28, 927–998(1992).
  • Silverman MA , TempleJD: Cancer in the elderly patient. Unique aspects of presentation, management and screening.J. Fla. Med. Assoc.79, 89–92(1992).
  • Franceschi S , La Vecchia C: Cancer epidemiology in the elderly. Crit. Rev. Oncol. Hematol.39, 219–226(2001).
  • Hightower RD , NguyenHN, AveretteHE, HoskinsW, HarrisonT, SterenA: National survey of ovarian carcinoma IV: patterns of care and related survival for older patients.Cancer73, 377–383(1994).
  • Riggs JE : Rising ovarian cancer mortality in the elderly: a manifestation of differential survival.Gynecol. Oncol.58, 64–67(1995).
  • Ries LA : Ovarian cancer. Survival and treatment differences by age.Cancer71, 254–529(1993).
  • Edwards BK , BrownML, WingoPAet al.: Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment.J. Natl Cancer Inst.97, 1407–1427(2005).
  • Alberts DS , DahlbergS, GreenSJet al.: Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin–cyclophosphamide versus carboplatin–cyclophosphamide in stages III (suboptimal) and IV ovarian cancer.Cancer71, 618–627(1993).
  • Thigpen T , BradyMF, OmuraGAet al.: Age as prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group Experience.Cancer71, 606–614(1993).
  • Edmonson JH , SuJ, KrookJE: Treatment of ovarian cancer in elderly women.Cancer71, 615–617(1993).
  • Gershenson DM , MitchellMF, AtkinsonNet al.: Age contrasts in patients with advanced epithelial ovarian cancer.Cancer7, 638–643(1993).
  • Uyar D , FrasureHD, MarkmanM, von GruenigenVE: Treatment patterns by decade of life in elderly woman (≥ 70 years of age) with ovarian cancer.Gynecol. Oncol.98, 403–408(2005).
  • Berchuck A , KohlerM, BoenteMPet al.: Growth regulation and transformation of ovarian epithelium.Cancer71, 545–551(1993).
  • Yancik R : Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality.Cancer71, 517–523(1993).
  • Grover SA , CookEF, AdamJet al.: Delayed diagnosis of gynecologic tumors in elderly women: relation to national medical practice patterns.Am. J. Med.86, 151–157(1989).
  • Markman M , LewisJL, SaigoPet al.: Epithelial ovarian cancer in the elderly.Cancer71, 634–637(1993).
  • Chiara S , LionettoR, VincentiMet al.: Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy.Crit. Rev. Oncol. Hematol.37, 27–34(2001).
  • Young RC , BradyMF, WaltonLA, HomesleyHD, AveretteHE, LongHJ: Localized ovarian cancer in the elderly. The Gynecologic Oncology Group Experience.Cancer71, 601–605(1993).
  • Balducci L , BegheC: The application of the principles of geriatrics to the management of the older persons with cancer.Crit. Rev. Oncol. Hematol.35, 147–154(2000).
  • Repetto L , VenturinoA, VercelliMet al.: Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions.Cancer82, 760–751(1998).
  • Balducci L , ExtermannM: Cancer and aging. An evolving panorama.Hematol. Oncol. Clin. North Am.14, 1–16(2000).
  • Ceccaroni M , D‘AgostinoG, FerrandinaGet al.: Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study.Gynecol. Oncol.85, 445–450(2002).
  • Monfardini S , FerrucciL, FratinoLet al.: Validation of a multidimensional evaluation scale for use in elderly cancer patients.Cancer77, 395–401(1996).
  • Repetto L , FratinoL, AudisioRAet al.: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.J. Clin. Oncol.20, 494–502(2002).
  • Bristow RE , TomacruzRS, ArmstrongDK, TrimbleEL, MontzFJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.J. Clin. Oncol.20, 1248–1259(2002).
  • Fentiman IS : Treatment of cancer in the elderly.Br. J. Cancer64, 993–995(1991).
  • Fentiman IS , TirelliU, MonfardiniSet al.: Cancer in the elderly: why so badly treated?Lancet335, 1020–1022(1990).
  • Wimberg P , LehmannN, KimmigRet al.: Impact of the age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).Gynecol. Oncol.100, 300–307(2006).
  • Nordin AJ , ChinnDJ, MoloneyI, NaikR, de Barros Lopes A, Monaghan JM: Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol. Oncol.81, 447–455(2001).
  • Kirschner CV , DeSertoTM, IsaacsJHet al.: Surgical treatment of the elderly patient with gynecologic cancer.Surg. Gynecol. Obstet.170, 379–384(1990).
  • Lawton FG , HackerNF: Surgery for invasive gynaecologic cancer in the elderly female population.Obstet. Gynecol.76, 287–289(1990).
  • Levrant SG , FruchterRG, MaimanM: Radical hysterectomy for cervical cancer: morbidity and survival in relation to weight and age.Gynecol. Oncol.45, 317–322(1992).
  • Karanikas ID , LiakakosTD, KoundorakisSS, TzorakisSE, DendrinosSS: Emergency operations in the elderly: management and outcome.Int. Surg.81, 158–166(1996).
  • Niettinen P , PasanenP, SalomenPA, LahitinenJ, AlahvaE: The outcome of elderly patients after operation for acute abdomen.Ann. Chir. Gynaecol.85, 11–18(1996).
  • Canver C , NicholsRD, CoolerSDet al.: Influence of age on long term survival after coronary artery by-pass grafting.Ann. Thorac. Surg.62, 1123–1127(1996).
  • Kennedy AW , FlaggJS, WebsterKD: Gynecologic cancer in the very elderly.Gynecol. Oncol.32, 49–54(1989).
  • Susini T , ScambiaG, MargaritiPAet al.: Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients.Gynecol. Oncol.75, 437–443(1999).
  • Lichtinger M , AveretteH, PenalverM, Sevin BU: Major surgical procedures for gynaecologic malignancy in elderly women. South Med. J.79, 1506–1510(1986).
  • Wright JD , HerzogTJ, PowellMA: Morbidity of cytoreductive surgery in the elderly.Am. J. Obstet. Gynecol.190, 1398–1400(2004).
  • Sharma S , DriscollD, OdunsiKet al.: Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients.Am. J. Obstet. Gynecol.193, 2077–2082(2005).
  • Bruchim I , AltarasM, FishmanA: Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer.Gynecol. Oncol.86, 274–278(2002).
  • Cloven NG , ManettaA, BermanML, KohlerMF, DiSaiaPJ: Management of ovarian cancer in patients older than 80 years of age.Gynecol. Oncol.73, 137–139(1999).
  • Giannice R , SusiniT, FerrandinaGet al.: Systematic pelvic and aortic lymphadenectomy in elderly gynecologic oncologic patients.Cancer92, 2562–2568(2001).
  • Sundararajan V , HershmanD, GrannVR, JacobsonJS, NeugutAI: Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study.J. Clin. Oncol.20, 173–178(2002).
  • van Rijswijk RE , VermorkenJB: Drug therapy for gynaecological cancer in older women.Drugs Aging17, 13–32(2000).
  • Balducci L , CorcoranMB: Antineoplastic chemotherapy of the older cancer patient.Hematol. Oncol. Clin. North Am.144, 193–212(2000).
  • Balducci L , BegheC: Pharmacology of chemotherapy in the older cancer patient.Cancer Control6, 466–470(1999).
  • Markman M , LewisJL, SaigoPet al.: Epithelial ovarian cancer in the elderly.Cancer71, 634–637(1993).
  • Lipschitz DA : Age-related declines in hematopoietic reserve capacity.Semin. Oncol.22, 3–5(1995).
  • Monfardini S , SorioR, Hoctin Boes G, Kaye S, Serraino D: Entry and Evaluation of Elderly Patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer76, 333–338(1995).
  • Hutchins LF , UngerJM, CrowleyJJet al.: Underrepresentation of patients 65 years of age or older in cancer-treatment trials.N. Engl. J. Med.341, 2061–2067(1999).
  • Pignata S , MonfardiniS: Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian cancer.Eur. J. Cancer36, 817–820(2000).
  • Pignata S , VermorkenJB: Ovarian cancer in the elderly.Crit. Rev. Oncol. Hematol.49, 77–86(2004).
  • ICON 2: randomized trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet352, 1571–1576(1998).
  • ICON collaborators: Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet360, 505–515(2002).
  • Freyer G , GeayJF, TouzetSet al.: Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.Ann. Oncol.16, 1795–1800(2005).
  • Higgins RV , NaumannRW, GardnerJ, Hall JB: Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin? Gynecol. Oncol.75, 464–467(1999).
  • Repetto L , Ausili-CefaroG, GalloC, RossiA, ManzioneL: Quality of life in elderly cancer patients.Ann. Oncol.12(Suppl. 3), S49–S52 (2001).
  • Balducci L , StantaG: Cancer and frailty: a coming epidemic.Hematol. Oncol. Clin. North Am.14, 235–250(2000).
  • Extermann M , AaproM, BernabeiRet al.: Task Force on CGA of the International Society of Geriatric Oncology. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).Crit. Rev. Oncol. Hematol.55, 241–252(2005).
  • Armstrong DK , BundyBN, WenzelLet al.: Intraperitoneal cisplatin an paclitaxel in ovarian cancer.N. Engl. J. Med.351, 34–43(2006).
  • Gronlund B , HogdallC, HansenHH, EngelholmSA: Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma.Cancer94, 1961–1967(2002).
  • Clarke-Pearson DL , Van Le L, Iveson T et al.: Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J. Clin. Oncol.19, 3967–3975(2001).
  • Levy T , InbarM, MenczerJ, GrisaruD, GlezermanM, SafraT: Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.Gynecol. Oncol.95, 686–690(2004).
  • Gordon AN , FleagleJT, GuthrieD, ParkinDE, GoreME, LacaveAJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.J. Clin. Oncol.19, 3312–3322(2001).
  • Safra T , GroshenS, JeffersSet al.: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Analysis of toxicities and predictors of outcome.Cancer91, 90–100(2001).
  • Pignata S , VarrialeE, CasellaGet al.: A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.Ann. Oncol.11, 613–616(2000).
  • Baietta E , Di Leo A, Biganzoli L et al.: Phase II study of vinorelbine in patients with pre-treated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol.14, 2546–2551(1996).
  • Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J. Natl Cancer Inst.91, 66–72(1999).
  • Gridelli C , CigolariS, GalloCet al.: MILES Investigators: activity and toxicity of gemicitabine and gemicitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial.Lung Cancer31, 277–284(2001).
  • de Wit R , van der Burg ME, Gaast AVD, Logmans A, Stoter G, Verweij J: Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory or relapsing within 12 months after platinum-containing chemotherapy. Ann. Oncol.5, 656–657(1994).
  • Delva R , MegeM, GamelinEet al.: Maintien de l‘intensitè de dose d‘une chimiotherapie associant carboplatine, cyclophosphamide et etoposide chez la femme de plus de 70 ans atteinte d‘un cancer de l‘ovaire.Bull. Cancer83, 63–69(1996).
  • van der Vange N , GreggiS, BurgerCWet al.: Experience with hormonal therapy in advanced ovarian cancer. Acta Oncol.34, 813–820(1995).
  • Ahlgren JD , EllisonNM, GodliebRJet al.: Hormonal palliation of chemotherapy resistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology program.J. Clin. Oncol.11, 1957–1968(1993).
  • van der Velden J , GitshG, WainGVet al.: Tamoxifen in patients with advanced epithelial ovarian cancer.Int. J. Gynecol. Cancer5, 301–305(1995).
  • Veenhof CH , van der Burg ME, Nooy M et al.: Phase II study of high-dose megestrol acetate in patients with advanced ovarian cancer Eur. J. Cancer30, 697–698(1994).
  • Tumolo S , RaoBR, van der Burg ME et al.: Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group study. Eur. J. Cancer30, 911–914(1994).
  • Cornelison TL , ReedE: Dose intensity of high-dose carboplatin in refractory ovarian carcinoma relative to age.Cancer71, 650–655(1993).
  • Wright JG , BoddyAV, HighleyM, FenwickK, McGillA, CalvertAH: Estimation of glomerular filtration rate in cancer patients.Br. J. Cancer84, 452–459(2001).
  • Marx GM , SteerCB, GalaniEet al.: Evaluation of the Cockroft Gault, Jeliffe and Wright formulae in estimating renal function in elderly patients.Proc. Am. Soc. Clin. Oncol.20, A1486 (2002).
  • Trimble EL , AdamsJD, VenaDet al.: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103.J. Clin. Oncol.11, 2405–2410(1993).
  • Bicher A , SarosyG, KohnEet al.: Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.Cancer71, 594–600(1993).
  • Fennelly D , AghajanianC, ShapiroFet al.: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.J. Clin. Oncol.15, 187–192(1997).
  • Andersson H , BomanK, RidderheimMet al.: An updated analysis of a randomized study of single agent paclitaxel given weekly vs every 3 weeks to patients with ovarian cancer treated with prior platinum therapy. Proc. Am. Soc. Clin. Oncol.19, A1505 (2000).
  • Newcomb PA , CarbonePP: Cancer treatment and age: patient perspectives.J. Natl Cancer Inst.85, 1580–1584(1993).
  • Guidozzi F : Living with ovarian cancer.Gynecol. Oncol.50, 202–207(1993).
  • Gomez H , MasL, CasanovaLet al.: Elderly patients with aggressive non-Hodgkin‘s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two subgroups with different hematologic toxicity.J. Clin. Oncol.16, 2352–2358(1998).
  • Zinzani PG , StortiS, ZaccariaAet al.: Elderly aggressive non-Hodgkin‘s lymphoma: first line VNCOP-B regimen: experience on 350 patients.Blood94, 33–38(1999).
  • Seidenfeld J , PiperM, FlammCet al.: Epoietin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials.J. Natl Cancer Inst.93, 1204–1214(2001).
  • Aapro MS , CellaD, ZagariM: Age, anemia, and fatigue.Semin. Oncol.29(Suppl. 8), 55–59(2002).
  • Kurz C h, Marth Ch, Windbichler G et al.: Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol. Oncol.65, 461–466(1997).
  • Heddens D , AlbertsD, HanniganEet al.: Prediction of the need for red cell trasfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment.Gynecol. Oncol.86, 239–243(2002).
  • Demetri GD , KrisM, WadeJet al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study.J. Clin. Oncol.16, 3412–3425(1998).
  • Cleeland CS , DemetriGD, GlaspyJet al.: Identifying haemoglobin levels for optimal quality of life. Results of an incremental analysis.Proc. Am. Soc. Clin. Oncol.16, A2215 (1999).
  • Fitch MI , GrayRE, FranssenE: Perspectives on living with ovarian cancer: old women‘s views.Oncol. Nurs. Forum9, 1433–1442(2001).
  • Ferrell B , CullinaneCA, ErvineKet al.: Perspectives on the impact of ovarian cancer: women‘s views of quality of life.Oncol. Nurs. Forum32(6), 1143–1149(2005).
  • Colussi AM , MazzerL, CandottoDet al.: The elderly cancer patients: a nursing perspective.Crit. Rev. Hematol. Oncol.39, 235–245(2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.